A point-of-care glucose system is a complete measurement device, not an enzyme vial attached to an electrode. Its result depends on glucose recognition, electron or peroxide transfer, sample filling, membrane transport, hematocrit, temperature, strip manufacturing, reader electronics, calibration, software, packaging, and user technique. Enzyme selection is central, but it must be evaluated within this system.
This guide focuses on disposable whole-blood glucose strips and related biosensors. It distinguishes glucose oxidase and major glucose dehydrogenase architectures, explains whole-blood and device-specific risks, and outlines a development path from enzyme screening to finished-system verification.
Our product offerings:
Diabetes and Blood Glucose Testing Enzymes
| Architecture | Enzyme Reaction | Transduction | Principal Design Questions |
|---|---|---|---|
| GOx peroxide sensor | Glucose oxidase uses oxygen and forms hydrogen peroxide | Electrochemical peroxide detection or optical indicator | Oxygen, peroxide potential, reducing and electroactive interferents |
| GOx mediated sensor | Electrons are transferred through a mediator, with possible oxygen competition | Mediator oxidation/reduction at electrode | Mediator compatibility, oxygen response, enzyme orientation |
| FAD-GDH sensor | FAD-dependent GDH transfers electrons to a suitable acceptor or mediator | Electrochemical current | Substrate specificity, mediator kinetics, residual oxygen response |
| PQQ-GDH sensor | PQQ-dependent GDH transfers electrons to an acceptor | Electrochemical current | Cross-response to non-glucose sugars for the specific enzyme/device |
| NAD(P)-GDH microfluidic system | GDH reduces a soluble nicotinamide cofactor | Optical or secondary electrochemical detection | Cofactor retention, blank, additional reaction steps |
“GDH” covers enzymes with different cofactors, acceptors, structures, substrate ranges, and suitable mediators. Cross-reactivity data for one PQQ-GDH or FAD-GDH product should not be assigned to another preparation. GOx products also differ in source, glycosylation, activity method, stability, and suitability for immobilization.
The supplier specification should identify enzyme family, source, cofactor or prosthetic group, activity definition, electron acceptor, substrate specificity, formulation, and relevant side activities. Device-level testing must confirm oxygen and alternate-sugar response.
Hematocrit changes the proportion of plasma, viscosity, capillary flow, diffusion, and access of glucose to the sensor layer. A single correction factor is rarely sufficient across all strip geometries and glucose concentrations. The effect may interact with temperature, sample volume, membrane properties, and fill time.
Whole-blood devices may report plasma-equivalent glucose according to their calibration model. This does not make the underlying specimen identical to plasma. The conversion, calibration, and performance claims belong to the complete device.
| Whole-Blood Variable | Possible Effect | Device Feature Involved | Evaluation Approach |
|---|---|---|---|
| Hematocrit | Bias from plasma fraction, viscosity and diffusion | Capillary channel, membrane, electrode and algorithm | Factorial study across hematocrit and glucose ranges |
| Oxygen tension | Competition or limitation in oxidase systems | Enzyme layer, membrane, mediator and geometry | Test intended oxygen range at multiple glucose levels |
| Sample volume | Incomplete wetting or concentration gradients | Fill detection and reagent distribution | Minimum-volume and underfill challenges |
| Temperature | Changed kinetics, diffusion, viscosity and electronics | Enzyme, strip materials, reader compensation | Operate across claimed environmental range |
| Electroactive compounds | Direct current at working potential | Electrode and mediator potential | Finished-device interference study |
| Alternate sugars | Enzyme-dependent positive response | Recognition enzyme | Specific cross-reactant testing based on enzyme and use setting |
A mediator should accept electrons efficiently from the reduced enzyme and exchange them with the electrode at a potential that limits direct oxidation of interferents. Its redox potential, solubility, stability, toxicity, diffusion, and compatibility with printing and drying all matter. A mediator that performs well in solution may migrate during storage or crystallize in a dry strip.
Direct electron transfer is attractive because it can reduce mediator dependence, but the enzyme's redox center may be buried or incorrectly oriented. Claims of direct transfer should be supported by electrochemical evidence and control experiments rather than inferred from current alone.
Membranes can limit glucose flux, reduce oxygen imbalance, exclude cells, block interferents, retain mediator, and protect the enzyme. They can also slow response, foul, swell, delaminate, or change with humidity and aging. The enzyme formulation, membrane chemistry, electrode, adhesive, and plastic housing should be evaluated as one material system.
Printing or dispensing variation changes enzyme mass and mediator distribution. Drying affects residual activity and layer morphology. Electrode dimensions, resistance, spacer thickness, capillary geometry, and seal alignment change the measured current and sample fill. Lot-to-lot verification should therefore include physical and functional controls.
Calibration links the electrochemical or optical response to reported glucose. Strip-lot changes in enzyme activity, mediator, electrode, and layer thickness can shift slope or intercept. Some systems use lot codes or factory calibration, while others rely on controlled manufacturing to minimize lot adjustment. The approach should prevent users from applying an incorrect calibration.
Calibration materials must represent the device response appropriately. Aqueous glucose solutions may not reproduce hematocrit, viscosity, oxygen, or diffusion of whole blood. Patient-sample comparison remains necessary.
Dry strips are sensitive to moisture, temperature, oxygen, light, and mechanical damage. Stability studies should cover unopened shelf-life, transport, open-vial or open-pouch use, and claimed operating conditions. Residual enzyme activity alone is insufficient; glucose recovery, blank, precision, response time, hematocrit response, and calibration stability should be monitored.
FDA's September 2020 guidance addresses prescription point-of-care blood glucose monitoring systems and recommends performance studies and submission information for those devices. It is distinct from FDA guidance for over-the-counter self-monitoring systems. Intended user and use setting should therefore be defined early.
ISO 15197:2013 remains the current published international standard for self-testing blood-glucose monitoring systems and was confirmed in 2018. A third edition is under development as a committee draft at the time of writing. Developers should apply the current published edition and monitor the draft without describing it as an effective requirement.
POCT performance includes more than strip chemistry. Sample application, underfilling, delayed dosing, repeat dosing, contaminated hands, extreme temperature, altitude, humidity, and meter maintenance can change results or error rates. The design should either tolerate foreseeable variation or detect it and prevent an apparently valid result.
Studies should reflect the intended operators and settings. A system for trained hospital staff may face high testing frequency, disinfection, multiple patient populations, and challenging clinical matrices. A self-testing system has different labeling, usability, and error-prevention needs. These use cases should not be combined merely because the same enzyme family is used.
| Observed behavior | Priority checks |
|---|---|
| Bias depends on hematocrit | Plasma-volume effect, diffusion, fill, membrane transport, electrode geometry, and correction algorithm |
| High-glucose samples flatten | Enzyme or mediator capacity, electrode range, oxygen competition, reagent volume, and calibration model |
| Strip lots differ but extracted enzyme activity agrees | Deposition, drying, mediator, membrane, electrode printing, strip coding, and package moisture |
| Cold testing is slow but endpoint recovers | Enzyme kinetics, viscosity, rehydration, diffusion, and temperature compensation |
| Unexpected response to another sugar | Enzyme specificity, mediator pathway, claimed medications, and concentration-dependent interference |
Investigations should preserve the complete meter-strip-lot relationship. Testing enzyme in solution is informative, but it cannot reproduce transport, electrochemistry, calibration coding, or fill detection. A system result should be decomposed only with controls that reconnect each component to finished performance.
